Literature DB >> 23853561

Characterization of REM sleep without atonia in patients with narcolepsy and idiopathic hypersomnia using AASM scoring manual criteria.

Lourdes M DelRosso1, Andrew L Chesson, Romy Hoque.   

Abstract

INTRODUCTION: The AASM Manual for the Scoring of Sleep and Associated Events (Manual) has provided standardized definitions for tonic and phasic REM sleep without atonia (RSWA). This study used Manual criteria to characterize REM sleep in patients with narcolepsy and idiopathic hypersomnia (IH).
METHODS: A retrospective review of PSG data from ICSD-2 defined patients with narcolepsy or IH, performed by two board certified sleep medicine physicians. Data compiled included REM sleep epochs and the presence in REM sleep of epochs scored as sustained muscle activity (tonic), and excessive transient muscle activity (phasic) as defined by Manual criteria.
RESULTS: PSG data from 8 narcolepsy patients (mean age: 27.5 years; age range: 11-55) showed mean ± standard deviation values for: total REM sleep epochs 205 ± 46.1; RSWA/ phasic epochs 56.1 ± 25.4; and RSWA/tonic epochs 15.0 ± 10.7. PSG data from 8 IH patients (mean age: 33.1 years; age range: 20-57) showed mean ± standard deviation values of total REM sleep epochs 163.8 ± 67.9; RSWA/phasic epochs 6.2 ± 3.5; and RSWA/tonic epochs 0.2 ± 0.4. Comparison revealed intergroup differences in phasic REM sleep (p < 0.01) and tonic REM sleep (p < 0.01) were significantly increased in narcoleptics compared to IH.
CONCLUSION: Our retrospective analysis showed that RSWA phasic activity and RSWA tonic activity are significantly increased in patients meeting ICSD-2 criteria for narcolepsy compared to patients meeting ICSD-2 criteria for IH. This robust difference, with further validation, could be useful as electrophysiological criteria differentiating the two disorders and understanding the physiological differences.

Entities:  

Keywords:  Narcolepsy; REM sleep without atonia; idiopathic hypersomnia; phasic; rapid eye movement sleep; tonic

Mesh:

Year:  2013        PMID: 23853561      PMCID: PMC3671332          DOI: 10.5664/jcsm.2836

Source DB:  PubMed          Journal:  J Clin Sleep Med        ISSN: 1550-9389            Impact factor:   4.062


  19 in total

1.  Hypocretinergic control of spinal cord motoneurons.

Authors:  Jack Yamuy; Simon J Fung; Mingchu Xi; Michael H Chase
Journal:  J Neurosci       Date:  2004-06-09       Impact factor: 6.167

2.  Motor dyscontrol in narcolepsy: rapid-eye-movement (REM) sleep without atonia and REM sleep behavior disorder.

Authors:  C H Schenck; M W Mahowald
Journal:  Ann Neurol       Date:  1992-07       Impact factor: 10.422

3.  Neurons containing hypocretin (orexin) project to multiple neuronal systems.

Authors:  C Peyron; D K Tighe; A N van den Pol; L de Lecea; H C Heller; J G Sutcliffe; T S Kilduff
Journal:  J Neurosci       Date:  1998-12-01       Impact factor: 6.167

4.  The association between narcolepsy and REM behavior disorder (RBD).

Authors:  S Nightingale; J C Orgill; I O Ebrahim; S F de Lacy; S Agrawal; A J Williams
Journal:  Sleep Med       Date:  2005-05       Impact factor: 3.492

5.  Evaluation of hypothalamic-specific autoimmunity in patients with narcolepsy.

Authors:  Jose E Martínez-Rodríguez; Lidia Sabater; Francesc Graus; Alex Iranzo; Joan Santamaria
Journal:  Sleep       Date:  2007-01       Impact factor: 5.849

6.  REM sleep behavior disorder and REM sleep without atonia as an early manifestation of degenerative neurological disease.

Authors:  Stuart J McCarter; Erik K St Louis; Bradley F Boeve
Journal:  Curr Neurol Neurosci Rep       Date:  2012-04       Impact factor: 5.081

7.  Narcolepsy presenting as REM sleep behaviour disorder.

Authors:  Anastasios Bonakis; Robin S Howard; Adrian Williams
Journal:  Clin Neurol Neurosurg       Date:  2008-03-17       Impact factor: 1.876

8.  Isolated mediotegmental lesion causing narcolepsy and rapid eye movement sleep behaviour disorder: a case evidencing a common pathway in narcolepsy and rapid eye movement sleep behaviour disorder.

Authors:  J Mathis; C W Hess; C Bassetti
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-04       Impact factor: 10.154

9.  REM sleep characteristics in narcolepsy and REM sleep behavior disorder.

Authors:  Yves Dauvilliers; Sylvie Rompré; Jean-François Gagnon; Mélanie Vendette; Dominique Petit; Jacques Montplaisir
Journal:  Sleep       Date:  2007-07       Impact factor: 5.849

Review 10.  The neurotransmitters of sleep.

Authors:  Jerome M Siegel
Journal:  J Clin Psychiatry       Date:  2004       Impact factor: 4.384

View more
  6 in total

Review 1.  Central Disorders of Hypersomnolence: Focus on the Narcolepsies and Idiopathic Hypersomnia.

Authors:  Zeeshan Khan; Lynn Marie Trotti
Journal:  Chest       Date:  2015-07       Impact factor: 9.410

2.  Defining disrupted nighttime sleep and assessing its diagnostic utility for pediatric narcolepsy type 1.

Authors:  Kiran Maski; Fabio Pizza; Shanshan Liu; Erin Steinhart; Elaina Little; Alicia Colclasure; Cecilia Diniz Behn; Stefano Vandi; Elena Antelmi; Edie Weller; Thomas E Scammell; Giuseppe Plazzi
Journal:  Sleep       Date:  2020-10-13       Impact factor: 5.849

3.  Nocturnal REM Sleep Without Atonia Is a Diagnostic Biomarker of Pediatric Narcolepsy.

Authors:  Saadoun Bin-Hasan; Aleksandar Videnovic; Kiran Maski
Journal:  J Clin Sleep Med       Date:  2018-02-15       Impact factor: 4.062

Review 4.  Disrupted nighttime sleep and sleep instability in narcolepsy.

Authors:  Kiran Maski; Emmanuel Mignot; Giuseppe Plazzi; Yves Dauvilliers
Journal:  J Clin Sleep Med       Date:  2022-01-01       Impact factor: 4.062

5.  Polysomnographic Assessment of Sleep Comorbidities in Drug-Naïve Narcolepsy-Spectrum Disorders--A Japanese Cross-Sectional Study.

Authors:  Taeko Sasai-Sakuma; Akihiko Kinoshita; Yuichi Inoue
Journal:  PLoS One       Date:  2015-08-31       Impact factor: 3.240

6.  Prevalence of near-death experiences in people with and without REM sleep intrusion.

Authors:  Daniel Kondziella; Jens P Dreier; Markus Harboe Olsen
Journal:  PeerJ       Date:  2019-08-27       Impact factor: 2.984

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.